Luo Kai, Zhang Qi-Liang, Zhang Xiao-Yang, Zhou Zi-Jie, Pan Yan-Jun, Zhu Zhong-Qun, Chen Qiang, Zheng Jing-Hao, He Xiao-Min, Zhang Wei
Department of Cardiothoracic Surgery, Shanghai Children's Medical Center, Heart Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Department of Cardiac Surgery, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Front Cardiovasc Med. 2024 Sep 18;11:1447487. doi: 10.3389/fcvm.2024.1447487. eCollection 2024.
This study aims to assess the early to mid-term clinical efficacy of expanded polytetrafluoroethylene (ePTFE) trileaflet valved conduits in pediatric right ventricular outflow tract reconstruction for congenital heart disease.
We conducted a retrospective analysis of pediatric patients who underwent right ventricular outflow tract (RVOT) reconstruction using ePTFE trileaflet valved conduits at two cardiac centers in China, between January 2017 and June 2023. The main assessment criterion was the functionality of the prosthetic pulmonary valve conduit.
A total of 162 pediatric patients were included, with follow-up periods ranging from 0.1 to 5 years post-discharge, and a median follow-up duration of 1 year (interquartile range: 1, 2). Three patients (1.9%) required re-operation due to conduit obstruction. During follow-up, pulmonary valve flow velocities were recorded as <3 m/s in 134 patients (82.7%), between 3 and 4 m/s in 24 patients (14.8%), and >4 m/s in 4 patient (2.5%). Mild pulmonary valve regurgitation was noted in 148 patients (91.4%), and moderate pulmonary valve regurgitation was noted in 14 patients (8.6%), with no instances of more than moderate pulmonary valve regurgitation.
The ePTFE trileaflet valved conduit, known for its accessibility and simplicity in manufacturing, demonstrates favorable early to mid-term clinical outcomes in pediatric RVOT reconstruction.
本研究旨在评估膨体聚四氟乙烯（ePTFE）三叶瓣带瓣管道在小儿先天性心脏病右心室流出道重建中的早期至中期临床疗效。
我们对2017年1月至2023年6月期间在中国两个心脏中心接受使用ePTFE三叶瓣带瓣管道进行右心室流出道（RVOT）重建的小儿患者进行了回顾性分析。主要评估标准是人工肺动脉瓣管道的功能。
共纳入162例小儿患者，出院后随访时间为0.1至5年，中位随访时间为1年（四分位间距：1，2）。3例患者（1.9%）因管道梗阻需要再次手术。随访期间，134例患者（82.7%）的肺动脉瓣流速记录为<3m/s，24例患者（14.8%）的流速在3至4m/s之间，4例患者（2.5%）的流速>4m/s。148例患者（91.4%）出现轻度肺动脉瓣反流，14例患者（8.6%）出现中度肺动脉瓣反流，无超过中度肺动脉瓣反流的情况。
ePTFE三叶瓣带瓣管道以其易于获取和制造简单而闻名，在小儿RVOT重建中显示出良好的早期至中期临床结果。
